Booth Gardner Parkinson's Care Center, Evergreen Neuroscience Institute , Evergreen Hospital Medical Center, Kirkland, WA 98034, USA.
Int J Neurosci. 2011 Nov;121(11):622-5. doi: 10.3109/00207454.2011.602774. Epub 2011 Aug 10.
To evaluate the potential of onabotulinum toxin A (Botox®, Allergan, Inc., Irvine, California) in the treatment of restless legs syndrome (RLS).
A single-arm, open-label pilot trial of onabotulinum toxin A was conducted to determine its usefulness as an injectable treatment for RLS.
The primary outcome measure, change in score on the International Restless Legs Syndrome Scale, showed a statistically significant improvement in RLS during the first 4 weeks after treatment. Two of the secondary outcome measures, pain (measured using a visual analog scale) and patients' global impression of severity of illness also showed improvement.
Onabotulinum toxin A warrants further study in RLS. Increasing the drug dosage, changing the dosing schedule, and increasing the number of injection sites may result in greater activity and longer duration of action.
评估肉毒杆菌毒素 A（Botox®，Allergan，Inc.，加利福尼亚州欧文）在治疗不宁腿综合征（RLS）中的潜力。
进行了一项单臂、开放标签的博妥珠单抗 A 先导试验，以确定其作为 RLS 注射治疗的用途。
主要结局测量指标，国际不宁腿综合征量表评分的变化，在治疗后 4 周内显示 RLS 有统计学意义的改善。两个次要结局测量指标，疼痛（使用视觉模拟量表测量）和患者对疾病严重程度的整体印象也显示出改善。
肉毒杆菌毒素 A 在 RLS 中值得进一步研究。增加药物剂量、改变给药方案和增加注射部位数量可能会导致更大的活性和更长的作用持续时间。
